Why Inventiva S.A.’s (IVA) Stock Is Up 6.29%
As of Wednesday, October 21, Inventiva S.A.’s IVA share price has surged by 6.29%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Commentary & Analysis
Why Inventiva S.A.’s (IVA) Stock Is Up 11.20%
As of Wednesday, October 21, Inventiva S.A.’s IVA share price has surged by 11.20%, which has investors questioning if this is right time to sell.Tudor Pop
Why Inventiva S.A.’s (IVA) Stock Is Up 6.71%
As of Tuesday, October 20, Inventiva S.A.’s IVA share price has surged by 6.71%, which has investors questioning if this is right time to sell.Michael Rose
Why Inventiva S.A.’s (IVA) Stock Is Up 11.24%
As of Tuesday, October 20, Inventiva S.A.’s IVA share price has surged by 11.24%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Inventiva S.A.’s (IVA) Stock Is Up 7.84%
As of Thursday, October 15, Inventiva S.A.’s IVA share price has surged by 7.84%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | IVA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $891.8 | $222.9 | 45% |
|
| Shares Out (Mil) | 312.6 | 53.4 | 83% |
|
| Institutional Ownership | 94.4% | 92.9% | 65% |
|
| Float (Mil) | 163.0 | 40.9 | 70% |
|
| Beta | 1.00 | 0.95 | 60% |
|
| Avg Daily Volume (000s) | 3,570 | 513 | 89% |
|
| Price Change (52-week) |
(37.7%) | 46.3% | 26% |
|
| Growth | IVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.3% | 13.2% | 33% |
|
| Net Income (5yr) | (58.9%) | (10.1%) | 5% |
|
| EPS (5yr) | (12.9%) | 15.8% | 20 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (65.5%) | (15.7%) | 3% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IVA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($283) | ($44) | 5% |
|
| EPS (TTM) | ($1.051) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($110) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $50 | $2 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $143 | $4 | 47% |
|
| Enterprise Value (Q1) (Mil) | $707 | $175 | 37% |
|
| Valuation | IVA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.62 | 2.14 | 93% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IVA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.3% | 66.5% | 88% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (113.9%) | (47.2%) | 5% |
|
| ROE | (994.0%) | (53.5%) | 0% |
|
| Liabilities to Assets | 76.5% | 29.4% | 72% |
|
| F-Score | 4 | 2 | 34% |
|
Inventiva S.A. did not pass any screens on 10/26/2026.
